PDCD1 and neoplasm: Moreover, we observed that patients with a low p62 expression in tumor region had a better PFS (progression‐free survival, median PFS 10 months vs 2 months, Gehan–Breslow–Wilcoxon test, p  =  0.0068) and an improved OS (p  =  0.0007, Figure 7E) after anti‐PD‐1 treatment.